First Patient Procedure in the World is Performed at Olympia Medical Center Los Angeles Using Adult Stem Cells to Enhance Surgical Outcome for Degenerative Spinal Disease
Director of Research and Education at Olympia Medical Center Los Angeles, neurosurgeon, Carl Lauryssen,M.D., completed the first procedure using a highly concentrated, pure population of adult stem cells that originates in bone marrow and is collected from live, healthy donors for optimal cell functionality. Up Until Now, There was No Available Pure Adult Stem Cell on the Market
Dr. Carl Lauryssen, a Neurosurgeon and Director of Research and Education at Olympia Medical Center in Los Angeles, CA, completed the first procedure using PureGen. Pablo Pazmino, M.D. assisted in the surgery. Dr. Lauryssen has twice been awarded the Young Investigator Award from the American Association of Neurological Surgeons for his work on cervical disorders and stem cell research. The patient underwent a L4-S1 posterolateral fusion. “I believe in the promise of stem cells for treating spinal disorders as they pose minimal inflammatory side effects and have the capacity to repair and regenerate bone. I believe the PureGen cell has the potential for providing surgeons with better clinical outcomes in spinal fusion,” stated Dr. Lauryssen.
The PureGen osteoprogenitor cell allograft facilitates bone fusion, and is marketed exclusively by Alphatec Spine. PureGen is an adult stem cell that provides the osteogenic factors needed for bone remodeling without the potential complications of autograft. Applied at the site of a musculoskeletal defect, PureGen mimics the regenerative environment of youthful tissues by increasing the concentration of stem cells available to repair tissue and build bone.
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine. PureGen is a highly concentrated, pure population of adult stem cells that originates in bone marrow and is collected from live, healthy donors for optimal cell functionality. Unlike current commercially available stem cell products with an unknown population of adult stem cells and harvested from cadaveric donor tissue, PureGen delivers a similar potency of a pure adult stem cell without the need for cultural expansion. Up until today, there was no available pure adult stem cell on the market.
“The PureGen osteoprogenitor cell is an extremely powerful cell that has both pluripotent potential and osteogenic differentiation. Our preclinical results underscore the ability of this cell to differentiate to bone faster and more efficiently than either bone marrow aspirate or mesenchymal stem cells,” said Dirk Kuyper, the Company's President and CEO.
About Olympia Medical Center: Olympia Medical Center is a physician owned hospital located in the heart of Los Angeles and has been providing medical care to its community since 1948. Services at the 204-bed acute care hospital include comprehensive inpatient and outpatient services and a 24-hour emergency room. The hospital is dedicated to clinical excellence and delivering health care services in a patient-centered, community focused environment. Services include the California Digestive Diseases Institute, the Los Angeles Center for Spine Care and Research, the Southern California Sports Medicine Institute, the center for Wound Management and Hyperbaric Medicine, the Continent Ostomy Center, the Center for Geriatric Health, Reflections and the Memory Institute. Olympia Medical Center is fully accredited by the Joint Commission on Accreditation of Health Care Organizations, the nation’s oldest and largest hospital accreditation agency. To learn more about Olympia Medical Center, visit www.olympiamedicalcenter.com.
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, The Company also markets its spine products in Europe. In Asia, the Company markets a broad line of spine and orthopedic products through its subsidiary, Alphatec Pacific, Inc.